Abstract
Rationale
Preclinical studies suggest that medications enhancing the brain gamma amino butyric acid (GABA) system attenuate the rewarding effects of stimulants including nicotine. These preclinical studies have not been followed up in systematic human studies.
Objectives
This study was conducted to examine the effects of a GABAergic medication, tiagabine, on acute physiological and subjective effects of intravenous (i.v.) nicotine and on tobacco withdrawal symptoms in overnight abstinent smokers. The proposed mechanism of action for tiagabine is selective inhibition of GABA transporter type I, which leads to increases in synaptic GABA levels.
Methods
Eight male and four female smokers participated in a double-blind, placebo-controlled, crossover study. In each of three experimental sessions, participants were treated orally with a single 4- or 8-mg dose of tiagabine or placebo. Two hours following the medication treatment, participants received i.v. saline, followed 30 min later by 1.5 mg/70 kg i.v. nicotine.
Results
Tiagabine treatment did not affect the heart rate or blood pressure changes induced by nicotine. There was a significant treatment effect for the subjective responses to nicotine, such that tiagabine, compared to placebo, attenuated the ratings of “good effects” and “drug liking.” Tiagabine treatment at 8 mg attenuated the craving for cigarettes and enhanced the cognitive performance in the Classical Stoop Tests, compared to placebo or 4 mg tiagabine condition.
Conclusions
These results suggest that GABA enhancing medication tiagabine may reduce the rewarding effects of nicotine and improve cognitive performance in abstinent smokers. The utility of GABA medications for smoking cessation needs to be examined further in controlled clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benowitz NL (1996) Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36:597–613
Berigan T (2002) Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry 47(8):788
Bevins RA, Besheer J, Pickett KS (2001) Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression. Pharmacol Biochem Behav 68(1):135–145
Brodie MJ (1995) Tiagabine pharmacology in profile. Epilepsia 36(Suppl 6):S7–S9
Cook MR, Gerkovich MM, Graham C, Hoffman SJ, Peterson RC (2003) Effects of the nicotine patch on performance during the first week of smoking cessation. Nicotine Tob Res 5(2):169–180
Cousins MS, Stamat HM, de Wit H (2001) Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 3(2):123–129
Dalby NO (2000) GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 39(12):2399–2407
Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr (1999) A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31(1):76–86
Fan J, Flombaum JI, McCandliss BD, Thomas KM, Posner MI (2003) Cognitive and brain consequences of conflict. NeuroImage 18(1):42–57
Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG (1992) The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 220(2–3):197–201
Genton P, Guerrini R, Perucca E (2001) Tiagabine in clinical practice. Epilepsia 42(Suppl):342–345
Golden C (1978) Stroop color and word test: a manual for clinical and experimental uses. Stoelting Company, Chicago, IL
Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR (2003) Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 98(11):1625–1632
Gross TM, Jarvik ME, Rosenblatt MR (1993) Nicotine abstinence produces content-specific Stroop interference. Psychopharmacology 110(3):333–336
Heatherton TF, Kozlowski LT, Frecker T, Fagerström KO (1991) The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86(9):1119–1127
Henningfield JE, Miyasato K, Jasinski DR (1985) Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234(1):1–12
Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43(3):289–294
Hughes JR, Hatsukami DK (1997) Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. J Subst Abuse 9151–9159
Jones HE, Garrett BE, Griffiths RR (1999) Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J Pharmacol Exp Ther 288(1):188–197
Juliano LM, Brandon TH (1998) Reactivity to instructed smoking availability and environmental cues: evidence with urge and reaction time. Exp Clin Psychopharmacol 6(1):45–53
Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB (2002) Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70(1):216–227
Kos J, Hasenfratz M, Battig K (1997) Effects of a 2-day abstinence from smoking on dietary, cognitive, subjective, and physiologic parameters among younger and older female smokers. Physiol Behav 61(5):671–678
Lile JA, Stoops WW, Glaser PE, Hays LR, Rush CR (2004) Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend 76(1):81–91
Mancuso G, Warburton DM, Melen M, Sherwood N, Tirelli E (1999) Selective effects of nicotine on attentional processes. Psychopharmacology (Berl) 146(2):199–204
Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33(6):905–919
McNair D, Lorr M, Dropperman L (1971) Manual for profile of mood states. Educational and Industrial Testing Services, San Diego, CA
Novak V, Kanard R, Kissel JT, Mendell JR (2001) Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res 11(6):357–361
Paterson NE, Markou A (2002) Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. Synapse 44(4):252–253
Perkins KA, D'Amico D, Sanders M, Grobe JE, Wilson A, Stiller RL (1996) Influence of training dose on nicotine discrimination in humans. Psychopharmacology (Berl) 126(2):132–139
Pidoplichko VI, Noguchi J, Areola OO, Liang Y, Peterson J, Zhang T, Dani JA (2004) Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learn Mem 11(1):60–69
Provost SC, Woodward R (1991) Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology (Berl) 104(4):536–540
Quick MW, Lester RA (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53(4):457–478
Reeves D, Winter K, Kane R, Elsmore T, Bleiberg J (2002) ANAM 2001 User's Manual. National Cognitive Recovery Foundation, San Diego, CA
Rosenthal M (2003) Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64(10):1245–1249
Sayette MA, Hufford MR (1994) Effects of cue exposure and deprivation on cognitive resources in smokers. J Abnorm Psychol 103(4):812–818
Schachter SC (2001) Pharmacology and clinical experience with tiagabine. Expert Opin Pharmacother 2(1):179–187
Watkins SS, Koob GF, Markou A (2000) Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2(1):19–37
Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54(6):1063–1070
Werhahn KJ, Kunesch E, Noachtar S, Benecke R, Classen J (1999) Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 517(Pt 2):591–597
Wickens CD, Kessel C (1980) Processing resource demands of failure detection in dynamic systems. J Exp Psychol Hum Percept Perform 6(3):564–577
Zwanzger P, Baghai TC, Schule C, Minov C, Padberg F, Moller HJ, Rupprecht R (2001) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62(8):656–657
Zwanzger P, Eser D, Padberg F, Baghai TC, Schule C, Rotzer F, Ella R, Moller HJ, Rupprecht R (2003) Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 18(3):140–143
Acknowledgements
This research was supported by the National Institute on Drug Abuse grants P50-DA12762, K05-DA0454 (T.R.K.), R01-DA 14537, and K12 00167 (M.S.). We would like to thank the Biostudies nursing staff for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sofuoglu, M., Mouratidis, M., Yoo, S. et al. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology 181, 504–510 (2005). https://doi.org/10.1007/s00213-005-0010-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-0010-y